Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901537 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
A Phase 1 study, sponsored by Loma Linda University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00901537 is a Phase 1 study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 8 participants.
The verdict
NCT00901537, a Phase 1 study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of body, chemotherapy using cisplatin can slow down tumor growth and extend lifespan. The study drug, azacitidine, can block the ability of some cancer cells to replicate, and has been approved by the Food and Drug Administration for use in myelodysplastic syndrome, which is a slowly developing blood cell-related cancer. In laboratory and animal experiments using head and neck and lung cancer cells, azacitidine has been shown to be a cisplatin "helper", (that is, it makes cisplatin more effective in stopping the growth of head and neck and lung cancer. ) Since the combination of azacitidine and cisplatin has not been used in patients with head and neck or lung cancer, the investigators are performing this study combining azacitidine and cisplatin to find out what effects, good and/or bad, the study drug may have on patients with advanced head and neck or lung cancer. The investigators are doing this study because they would like to find a better treatment for these types of cancer.
Interventions
- DRUG Azacitidine and Cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00901537
The ClinicalTrials.gov registry entry for NCT00901537 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azacitidine and Cisplatin is the first listed.
NCT00901537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00901537 about?
NCT00901537 is a clinical study titled "Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer". The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of body, chemotherapy using cisplatin can slow down tumor growth and extend ...
What is the current status of trial NCT00901537?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00901537?
The interventions under investigation include: Azacitidine and Cisplatin (DRUG).
Who is sponsoring clinical trial NCT00901537?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.